JPWO2021046074A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021046074A5 JPWO2021046074A5 JP2022513923A JP2022513923A JPWO2021046074A5 JP WO2021046074 A5 JPWO2021046074 A5 JP WO2021046074A5 JP 2022513923 A JP2022513923 A JP 2022513923A JP 2022513923 A JP2022513923 A JP 2022513923A JP WO2021046074 A5 JPWO2021046074 A5 JP WO2021046074A5
- Authority
- JP
- Japan
- Prior art keywords
- specifically binds
- capture reagent
- subject
- reagent specifically
- information corresponding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025073876A JP2025118715A (ja) | 2019-09-03 | 2025-04-28 | 心血管リスク／イベントの予測及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895383P | 2019-09-03 | 2019-09-03 | |
| US62/895,383 | 2019-09-03 | ||
| PCT/US2020/048981 WO2021046074A1 (en) | 2019-09-03 | 2020-09-02 | Cardiovascular risk event prediction and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025073876A Division JP2025118715A (ja) | 2019-09-03 | 2025-04-28 | 心血管リスク／イベントの予測及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022546515A JP2022546515A (ja) | 2022-11-04 |
| JPWO2021046074A5 true JPWO2021046074A5 (https=) | 2023-08-28 |
| JP2022546515A5 JP2022546515A5 (https=) | 2023-08-28 |
| JP7712913B2 JP7712913B2 (ja) | 2025-07-24 |
Family
ID=72521733
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513923A Active JP7712913B2 (ja) | 2019-09-03 | 2020-09-02 | 心血管リスク／イベントの予測及びその使用 |
| JP2025073876A Pending JP2025118715A (ja) | 2019-09-03 | 2025-04-28 | 心血管リスク／イベントの予測及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025073876A Pending JP2025118715A (ja) | 2019-09-03 | 2025-04-28 | 心血管リスク／イベントの予測及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220349904A1 (https=) |
| EP (1) | EP4025916A1 (https=) |
| JP (2) | JP7712913B2 (https=) |
| KR (1) | KR20220057534A (https=) |
| CN (1) | CN114641692B (https=) |
| AU (1) | AU2020343243A1 (https=) |
| BR (1) | BR112022003666A2 (https=) |
| CA (1) | CA3151482A1 (https=) |
| IL (1) | IL290951A (https=) |
| MX (1) | MX2022002314A (https=) |
| WO (1) | WO2021046074A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025173327A1 (ja) * | 2024-02-14 | 2025-08-21 | Ｎｅｃソリューションイノベータ株式会社 | 罹患死亡可能性予測モデル、罹患死亡可能性予測方法、罹患死亡可能性予測装置、プログラム、及び記録媒体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001577A (en) | 1998-06-08 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| EP0786469B1 (en) | 1990-06-11 | 2006-03-01 | Gilead Sciences, Inc. | Methods of use of nucleic acid ligands |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US6458539B1 (en) | 1993-09-17 | 2002-10-01 | Somalogic, Inc. | Photoselection of nucleic acid ligands |
| US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
| WO2008056034A1 (en) * | 2006-11-10 | 2008-05-15 | Hytest Ltd. | Stable standards for bnp immunoassays |
| EP2302395B1 (en) * | 2006-06-07 | 2015-04-15 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| US7855054B2 (en) | 2007-01-16 | 2010-12-21 | Somalogic, Inc. | Multiplexed analyses of test samples |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| DK2172566T4 (da) | 2007-07-17 | 2022-06-13 | Somalogic Inc | Fremgangsmåde til generering af aptamerer med forbedrede off-rates |
| WO2012006632A2 (en) | 2010-07-09 | 2012-01-12 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| KR20120101064A (ko) * | 2009-11-13 | 2012-09-12 | 비쥐 메디신, 인코포레이티드 | 심근 경색의 위험 인자 및 예측 |
| EP2593566B1 (en) * | 2010-07-14 | 2018-01-24 | The Regents of The University of California | Biomarkers for diagnosis of transient ischemic attacks |
| CN103429753A (zh) | 2010-09-27 | 2013-12-04 | 私募蛋白质体公司 | 间皮瘤生物标记及其用途 |
| MX373248B (es) * | 2011-09-30 | 2020-05-11 | Somalogic Operating Co Inc | Prediccion de riesgo de evento cardiovascular y usos del mismo. |
| EP2835641A1 (en) * | 2013-08-09 | 2015-02-11 | Inotrem | Methods and kits for predicting the risk of having a cardiovascular disease or event |
| ES2792227T3 (es) * | 2014-09-26 | 2020-11-10 | Somalogic Inc | Predicción de evento de riesgo cardiovascular y usos de la misma |
| CN108291330A (zh) * | 2015-07-10 | 2018-07-17 | 西弗吉尼亚大学 | 卒中和卒中严重性的标志物 |
-
2020
- 2020-09-02 AU AU2020343243A patent/AU2020343243A1/en active Pending
- 2020-09-02 WO PCT/US2020/048981 patent/WO2021046074A1/en not_active Ceased
- 2020-09-02 MX MX2022002314A patent/MX2022002314A/es unknown
- 2020-09-02 CN CN202080060080.3A patent/CN114641692B/zh active Active
- 2020-09-02 KR KR1020227006316A patent/KR20220057534A/ko active Pending
- 2020-09-02 CA CA3151482A patent/CA3151482A1/en active Pending
- 2020-09-02 JP JP2022513923A patent/JP7712913B2/ja active Active
- 2020-09-02 EP EP20772497.2A patent/EP4025916A1/en active Pending
- 2020-09-02 BR BR112022003666A patent/BR112022003666A2/pt unknown
- 2020-09-02 US US17/637,128 patent/US20220349904A1/en active Pending
-
2022
- 2022-02-27 IL IL290951A patent/IL290951A/en unknown
-
2025
- 2025-04-28 JP JP2025073876A patent/JP2025118715A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zeller et al. | Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction | |
| Shah et al. | Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure | |
| Ibrahim et al. | A clinical and biomarker scoring system to predict the presence of obstructive coronary artery disease | |
| JP5271350B2 (ja) | 糖尿病に関連するバイオマーカーおよびその使用方法 | |
| Cho et al. | Korean Society of Heart Failure guidelines for the management of heart failure: definition and diagnosis | |
| Ketcham et al. | Coronavirus disease-2019 in heart transplant recipients in southeastern Michigan: a case series | |
| Wu et al. | Cardiac involvement in recovered patients from COVID-19: a preliminary 6-month follow-up study | |
| JP6944449B2 (ja) | 対象の細胞外液量状態のマーカーとしてのＭＲ−ｐｒｏＡＤＭ | |
| Gibson et al. | B-type natriuretic peptide predicts cardiac morbidity and mortality after major surgery | |
| Moon et al. | Risk stratification of myocardial injury after liver transplantation in patients with computed tomographic coronary angiography–diagnosed coronary artery disease | |
| RU2672561C2 (ru) | Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности | |
| JP2017530356A5 (https=) | ||
| Armillotta et al. | Predictive value of Killip classification in MINOCA patients | |
| Oba et al. | Effect of the epicardial adipose tissue volume on the prevalence of paroxysmal and persistent atrial fibrillation | |
| Agarwal et al. | Fibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study | |
| Ip et al. | Atrial fibrillation as a predictor of mortality in high risk COVID-19 patients: a multicentre study of 171 patients | |
| Astor et al. | N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK) | |
| Zhao et al. | Prognosis implication of N-terminal pro-B-type natriuretic peptide in adult patients with acute myocarditis | |
| Kanagala et al. | Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction | |
| Demir et al. | Platelet to lymphocyte ratio on admission and prognosis in patients with acute cardiogenic pulmonary edema | |
| Wu et al. | Impact of glycemic gap on 30-day adverse outcomes in patients with acute ST-segment elevation myocardial infarction | |
| Pusuroglu et al. | Long-term prognostic value of mean platelet volume in patients with hypertension | |
| Palazzuoli et al. | Osteoprotegerin and B-type natriuretic peptide in non-ST elevation acute coronary syndromes: relation to coronary artery narrowing and plaques number | |
| Dou et al. | Changes and significance of serum troponin in trauma patients: A retrospective study in a level I trauma center | |
| Shen et al. | Acute kidney injury and in-hospital mortality after coronary artery bypass graft versus percutaneous coronary intervention: a nationwide study |